Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: Acne Vulgaris - Pipeline Review, H1 2012

Research and Markets
Posted on: 11 Apr 12

Research and Markets (http://www.researchandmarkets.com/research/eb614d26/acne_vulgaris_pi) has announced the addition of Global Markets Direct's new report "Acne Vulgaris - Pipeline Review, H1 2012" to their offering.

Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H1 2012', provides an overview of the Acne Vulgaris therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. 'Acne Vulgaris - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Acne Vulgaris.

- A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Acne Vulgaris pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Acne Vulgaris therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/eb614d26/acne_vulgaris_pi

Source: Global Markets Direct

Business Wire
http://www.businesswire.com/

Last updated on: 11/04/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.